Abstract
Background Despite significant advancements in pediatric anesthesia training and guidelines, the incidence of severe critical events in children undergoing anesthesia in Asia remains under-researched. This knowledge gap is particularly pressing given the rare but life-threatening nature of such complications. While studies from high-income countries report a decline in pediatric anesthesia-related mortality, similar data from developing regions, including Asia, are sparse and suggest higher risks.
Objective The Peri-anesthetic Morbidity in Children in Asia (PEACH in Asia) study aims to provide a comprehensive assessment of the incidence and risk factors associated with severe critical events in pediatric anesthesia across Asia. This multinational, multicenter, prospective observational study seeks to enhance understanding of pediatric anesthesia-related risks and variability in practices within the region.
Methods The study will enroll children aged birth to 15 years undergoing elective or urgent diagnostic or surgical procedures requiring sedation or general anesthesia, with or without regional analgesia. Data collection will focus on severe critical events occurring during and up to 60 minutes post-anesthesia, including laryngospasm, bronchospasm, pulmonary aspiration, drug errors, anaphylaxis, cardiovascular instability, neurological damage, cardiac arrest, and post-anesthetic stridor. The study will also capture patient demographics, medical history, and procedural details to identify potential risk factors.
Results The pilot phase of the PEACH in Asia study, conducted from May to June 2023, included 330 patients from ten institutions across nine countries. Preliminary findings revealed a severe critical event incidence rate of 12.4% [95% CI: 9.2-16.4]. Based on these results, the main study plans to recruit approximately 10,958 children across 15 to 30 Asian countries to achieve robust statistical power and refine risk factor identification.
Conclusion The PEACH in Asia study represents a critical step towards understanding and mitigating the risks associated with pediatric anesthesia in Asia. By providing data-driven insights into the incidence of severe critical events and regional variations in anesthesia practices, this study aims to inform and improve pediatric anesthesia protocols across the continent.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000052803
Funding Statement
This research work, as part of the PEACH in Asia study project, was supported by Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics in Japan (2022-2023) and has been supported by MEXT KAKENHI Grant Number 24K13535 (since 2024).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study project is in compliance with all ethical principles of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines. The Institutional Review Board at Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan gave ethical approval for the PEACH in Asia study project as an international prospective observational multicenter study. Ethics requirement differs among countries and even within a given country. All participating institutions will receive formal ethics approval or a waiver, as appropriate.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
2
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos